Section 5 of 6
Economic information and modeling report
4 evidence topics · 1 source
Modeling overview
Summary
The retained comparator economic assessment evaluates Cinryze, Haegarda, and Takhzyro against no prophylaxis. ICER's 2021 observational real-world evidence update reported incremental costs per QALY gained of $30,070,000, $13,430,000, and $12,370,000, respectively. These are comparator cost-effectiveness estimates, not annual treatment costs, acquisition prices, or budget-impact estimates for lonvoguran ziclumeran. The report cautions that small denominators can produce extreme incremental cost-effectiveness ratios.
Comparator economic assessment: reference strategy
Comparator-treatment economic assessment: observational real-world evidence update
Comparator economic assessment: interpretation of incremental ratios
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.